Journal of clinical pharmacology (July 2016) SITE

  • J Clin Pharmacol. 2016;56 Suppl 7:S7-S10. Role of transporters in drug development. Arya V, Kiser JJ. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S11-22.  Role of hepatic drug transporters in drug development. Liu H, Sahi J. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S23-39. Importance of hepatic transporters in clinical disposition of drugs and their metabolites. Patel M, Taskar KS, Zamek-Gliszczynski MJ. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S40-58.  Impact of transporter polymorphisms on drug development: is it clinically significant? McLean C, Wilson A, Km RB. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S59-72. Comparing various In vitro prediction. Criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1. Vaidyanathan J, Yoshida K, Arya V, Zhang L. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S82-98.  Evaluation of proposed in vivo probe substrates and inhibitors for phenotyping transporter activity in humans. Momper JD, Tsunoda SM, Ma JD. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S99-S109. Transporter-enzyme interplay: deconvoluting effects of hepatic transporters and enzymes on drug disposition using static and dynamic mechanistic models. Varma MV, El-Kattan AF. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S122-31. The application of physiologically based Pharmacokinetic modeling to predict the role of drug transporters: scientific and regulatory perspectives. Pan Y, Hsu V, Grimstein M, Zhang L, Arya V, Sinha V, Grillo JA, Zhao P. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S132-42. More power to OATP1B1: an evaluation of sample size in pharmacogenetic studies using a rosuvastatin PBPK model for intestinal, hepatic, and renal transporter-mediated clearances. Emami Riedmaier A, Burt H, Abduljalil K, Neuhoff S. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S143-56. Use of PET imaging to evaluate transporter-mediated drug-drug interactions. Langer O. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S157-72. The role of transporters in the toxicity of chemotherapeutic drugs: focus on transporters for organic cations. Hucke A, Ciarimboli G. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S173-92. Causes and consequences of variability in drug transporter activity in pediatric drug therapy. Rodieux F, Gotta V, Pfister M, van den Anker JN. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S193-204. Review of transporter-related postmarketing requirement or postmarketing commitment studies. Fan Y, Sun B, Agarwal S, Zhang L. PubMed
  • J Clin Pharmacol. 2016;56 Suppl 7:S205-21. Effect of disease pathologies on transporter expression and function. Atilano-Roque A, Roda G, Fogueri U, Kiser JJ, Joy MS. PubMed